Together, these findings highlight the therapeutic relevance of FGFR4 and FGFR2 signaling in fusion-driven rhabdomyosarcoma and support the further development of FGFR-targeted approaches in this malignancy. Here, FGFR4 is linked to rhabdomyosarcoma.